Search

Iruela-Arispe, M L, M Lombardo, H C Krutzsch, J Lawler, and D D Roberts. 1999. “Inhibition of Angiogenesis by Thrombospondin-1 Is Mediated by 2 Independent Regions Within the Type 1 Repeats.”. Circulation 100 (13): 1423-31.

Sipes, J M, H C Krutzsch, J Lawler, and D D Roberts. 1999. “Cooperation Between Thrombospondin-1 Type 1 Repeat Peptides and Alpha(v)beta(3) Integrin Ligands to Promote Melanoma Cell Spreading and Focal Adhesion Kinase Phosphorylation.”. The Journal of Biological Chemistry 274 (32): 22755-62.

Streit, M, P Velasco, L F Brown, M Skobe, L Richard, L Riccardi, J Lawler, and M Detmar. 1999. “Overexpression of Thrombospondin-1 Decreases Angiogenesis and Inhibits the Growth of Human Cutaneous Squamous Cell Carcinomas.”. The American Journal of Pathology 155 (2): 441-52.

Hecht, J T, D Montufar-Solis, G Decker, J Lawler, K Daniels, and P J Duke. 1998. “Retention of Cartilage Oligomeric Matrix Protein (COMP) and Cell Death in Redifferentiated Pseudoachondroplasia Chondrocytes.”. Matrix Biology : Journal of the International Society for Matrix Biology 17 (8-9): 625-33.

Guo, N, V S Zabrenetzky, L Chandrasekaran, J M Sipes, J Lawler, H C Krutzsch, and D D Roberts. 1998. “Differential Roles of Protein Kinase C and Pertussis Toxin-Sensitive G-Binding Proteins in Modulation of Melanoma Cell Proliferation and Motility by Thrombospondin 1.”. Cancer Research 58 (14): 3154-62.

Crawford, S E, V Stellmach, J E Murphy-Ullrich, S M Ribeiro, J Lawler, R O Hynes, G P Boivin, and N Bouck. 1998. “Thrombospondin-1 Is a Major Activator of TGF-Beta1 in Vivo.”. Cell 93 (7): 1159-70.

Prete, Alessandro, Agnes S Lo, Peter M Sadow, Swati S Bhasin, Zeus A Antonello, Danica M Vodopivec, Soumya Ullas, et al. 2018. “Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.”. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24 (23): 6078-97.

Riessen, R, M Kearney, J Lawler, and J M Isner. 1998. “Immunolocalization of Thrombospondin-1 in Human Atherosclerotic and Restenotic Arteries.”. American Heart Journal 135 (2 Pt 1): 357-64.

Barabino, G A, R J Wise, V A Woodbury, B Zhang, K A Bridges, R P Hebbel, J Lawler, and B M Ewenstein. 1997. “Inhibition of Sickle Erythrocyte Adhesion to Immobilized Thrombospondin by Von Willebrand Factor under Dynamic Flow Conditions.”. Blood 89 (7): 2560-7.

Incardona, F, J Lawler, D Cataldo, A Panet, Y Legrand, J M Foidart, and C Legrand. 1996. “Heparin-Binding Domain, Type 1 and Type 2 Repeats of Thrombospondin Mediate Its Interaction With Human Breast Cancer Cells.”. Journal of Cellular Biochemistry 62 (4): 431-42.